APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Migraine Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Migraine Drugs Industry Growth and Trends Forecast to 2032

Report ID 174013430126 December 2025116 pages

Choose your research edition.

Industry ResearchMigraine Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Migraine Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Migraine Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Migraine Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Migraine Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Migraine Drugs include Abbott, Johnson & Johnson, Merck, Eli Lilly, Pfizer, Pfizer, Bayer, Winston Pharmaceuticals and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Migraine Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Migraine Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Migraine Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Migraine Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Migraine Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Migraine Drugs Market by Company

Abbott

Johnson & Johnson

Merck

Eli Lilly

Pfizer

Pfizer

Bayer

Winston Pharmaceuticals

Teva

Kowa Pharmaceuticals America

Impax

GlaxoSmithKline

Ethypharm

Endo International

AstraZeneca

Allergan

Migraine Drugs Segment by Type

Rizatriptan

Others Drug

Sumatriptan

Zolmitriptan

Migraine Drugs Segment by Application

Hospitals

Clinics

Household Use

Others

Migraine Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Migraine Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Migraine Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Rizatriptan Table 2. Major Company of Others Drug Table 3. Major Company of Sumatriptan Table 4. Major Company of Zolmitriptan Table 5. Global Migraine Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 7. Global Migraine Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global Migraine Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global Migraine Drugs Price by Type (2021-2026) & (US$/Unit) Table 11. Global Migraine Drugs Sales by Type (2027-2032) & (K Units) Table 12. Global Migraine Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global Migraine Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global Migraine Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global Migraine Drugs Price by Type (2027-2032) & (US$/Unit) Table 16. North America Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 17. North America Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 19. Europe Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 23. Latin America Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Migraine Drugs Industry Trends Table 27. Migraine Drugs Industry Drivers Table 28. Migraine Drugs Industry Opportunities and Challenges Table 29. Migraine Drugs Industry Restraints Table 30. Global Migraine Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Migraine Drugs Revenue Market Share by Company (2021-2026) Table 32. Global Migraine Drugs Sales by Company (2021-2026) & (K Units) Table 33. Global Migraine Drugs Sales Share by Company (2021-2026) Table 34. Global Migraine Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Migraine Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Migraine Drugs Major Company Production Sites and Headquarters Table 37. Global Migraine Drugs Company, Product Type & Application Table 38. Global Migraine Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Migraine Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Migraine Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Migraine Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Migraine Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global Migraine Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global Migraine Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global Migraine Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Migraine Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Migraine Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global Migraine Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global Migraine Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global Migraine Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Migraine Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Migraine Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global Migraine Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global Migraine Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Migraine Drugs Sales by Application (2027-2032) & (K Units) Table 59. Global Migraine Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global Migraine Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global Migraine Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global Migraine Drugs Price by Application (2027-2032) & (US$/Unit) Table 63. North America Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 64. North America Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 66. Europe Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 70. Latin America Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Abbott Company Information Table 74. Abbott Business Overview Table 75. Abbott Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Abbott Migraine Drugs Product Portfolio Table 77. Abbott Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Migraine Drugs Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Merck Migraine Drugs Product Portfolio Table 87. Merck Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Eli Lilly Migraine Drugs Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pfizer Migraine Drugs Product Portfolio Table 97. Pfizer Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Migraine Drugs Product Portfolio Table 102. Pfizer Recent Development Table 103. Bayer Company Information Table 104. Bayer Business Overview Table 105. Bayer Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Bayer Migraine Drugs Product Portfolio Table 107. Bayer Recent Development Table 108. Winston Pharmaceuticals Company Information Table 109. Winston Pharmaceuticals Business Overview Table 110. Winston Pharmaceuticals Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Winston Pharmaceuticals Migraine Drugs Product Portfolio Table 112. Winston Pharmaceuticals Recent Development Table 113. Teva Company Information Table 114. Teva Business Overview Table 115. Teva Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Teva Migraine Drugs Product Portfolio Table 117. Teva Recent Development Table 118. Kowa Pharmaceuticals America Company Information Table 119. Kowa Pharmaceuticals America Business Overview Table 120. Kowa Pharmaceuticals America Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Kowa Pharmaceuticals America Migraine Drugs Product Portfolio Table 122. Kowa Pharmaceuticals America Recent Development Table 123. Impax Company Information Table 124. Impax Business Overview Table 125. Impax Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Impax Migraine Drugs Product Portfolio Table 127. Impax Recent Development Table 128. GlaxoSmithKline Company Information Table 129. GlaxoSmithKline Business Overview Table 130. GlaxoSmithKline Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. GlaxoSmithKline Migraine Drugs Product Portfolio Table 132. GlaxoSmithKline Recent Development Table 133. Ethypharm Company Information Table 134. Ethypharm Business Overview Table 135. Ethypharm Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Ethypharm Migraine Drugs Product Portfolio Table 137. Ethypharm Recent Development Table 138. Endo International Company Information Table 139. Endo International Business Overview Table 140. Endo International Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Endo International Migraine Drugs Product Portfolio Table 142. Endo International Recent Development Table 143. AstraZeneca Company Information Table 144. AstraZeneca Business Overview Table 145. AstraZeneca Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. AstraZeneca Migraine Drugs Product Portfolio Table 147. AstraZeneca Recent Development Table 148. Allergan Company Information Table 149. Allergan Business Overview Table 150. Allergan Migraine Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Allergan Migraine Drugs Product Portfolio Table 152. Allergan Recent Development Table 153. North America Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. North America Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 155. North America Migraine Drugs Sales Market Share by Country (2021-2026) Table 156. North America Migraine Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 157. North America Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 158. North America Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 160. North America Migraine Drugs Market Share by Country (2021-2026) Table 161. North America Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America Migraine Drugs Market Share Forecast by Country (2027-2032) Table 163. Europe Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Europe Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 165. Europe Migraine Drugs Sales Market Share by Country (2021-2026) Table 166. Europe Migraine Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 167. Europe Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 168. Europe Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe Migraine Drugs Market Share by Country (2021-2026) Table 171. Europe Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe Migraine Drugs Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 175. Asia-Pacific Migraine Drugs Sales Market Share by Country (2021-2026) Table 176. Asia-Pacific Migraine Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 177. Asia-Pacific Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 178. Asia-Pacific Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Asia-Pacific Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 180. Asia-Pacific Migraine Drugs Market Share by Country (2021-2026) Table 181. Asia-Pacific Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Asia-Pacific Migraine Drugs Market Share Forecast by Country (2027-2032) Table 183. Latin America Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 184. Latin America Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 185. Latin America Migraine Drugs Sales Market Share by Country (2021-2026) Table 186. Latin America Migraine Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 187. Latin America Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 188. Latin America Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Latin America Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 190. Latin America Migraine Drugs Market Share by Country (2021-2026) Table 191. Latin America Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Latin America Migraine Drugs Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 195. Middle East and Africa Migraine Drugs Sales Market Share by Country (2021-2026) Table 196. Middle East and Africa Migraine Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 197. Middle East and Africa Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 198. Middle East and Africa Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Middle East and Africa Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 200. Middle East and Africa Migraine Drugs Market Share by Country (2021-2026) Table 201. Middle East and Africa Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Middle East and Africa Migraine Drugs Market Share Forecast by Country (2027-2032) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. Migraine Drugs Distributors List Table 206. Migraine Drugs Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Migraine Drugs Image Figure 2. Global Migraine Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Migraine Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Migraine Drugs Sales (2021-2032) & (K Units) Figure 5. Rizatriptan Image Figure 6. Global Rizatriptan Sales YoY Growth (2021-2032) & (K Units) Figure 7. Others Drug Image Figure 8. Global Others Drug Sales YoY Growth (2021-2032) & (K Units) Figure 9. Sumatriptan Image Figure 10. Global Sumatriptan Sales YoY Growth (2021-2032) & (K Units) Figure 11. Zolmitriptan Image Figure 12. Global Zolmitriptan Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Migraine Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Migraine Drugs Market Share by Type 2025 VS 2032 Figure 15. North America Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Migraine Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospitals Image Figure 28. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 29. Clinics Image Figure 30. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 31. Household Use Image Figure 32. Global Household Use Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Migraine Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Migraine Drugs Market Share by Application 2025 VS 2032 Figure 37. North America Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 38. North America Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 39. Europe Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Europe Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 43. Latin America Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 47. North America Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Migraine Drugs Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Migraine Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Rizatriptan
  • Others Drug
  • Sumatriptan
  • Zolmitriptan
Applications
  • Hospitals
  • Clinics
  • Household Use
  • Others
Companies covered
  • Abbott
  • Johnson & Johnson
  • Merck
  • Eli Lilly
  • Pfizer
  • Pfizer
  • Bayer
  • Winston Pharmaceuticals
  • Teva
  • Kowa Pharmaceuticals America
  • Impax
  • GlaxoSmithKline
  • Ethypharm
  • Endo International
  • AstraZeneca
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Migraine Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Migraine Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Migraine Drugs Market by Type
  6. 1.3.1 Rizatriptan
  7. 1.3.2 Others Drug
  8. 1.3.3 Sumatriptan
  9. 1.3.4 Zolmitriptan
  10. 1.4 Global Migraine Drugs Market Size by Type
  11. 1.4.1 Global Migraine Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Migraine Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Migraine Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Migraine Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Migraine Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Migraine Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Migraine Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Migraine Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Migraine Drugs Industry Trends
  2. 2.2 Migraine Drugs Industry Drivers
  3. 2.3 Migraine Drugs Industry Opportunities and Challenges
  4. 2.4 Migraine Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Migraine Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Migraine Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Migraine Drugs Price (2021-2026)
  4. 3.4 Global Migraine Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Migraine Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Migraine Drugs Company, Product Type & Application
  7. 3.7 Global Migraine Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Migraine Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Migraine Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Migraine Drugs Regional Status and Outlook
  1. 4.1 Global Migraine Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Migraine Drugs Historic Market Size by Region
  3. 4.2.1 Global Migraine Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Migraine Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Migraine Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Migraine Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Migraine Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Migraine Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Migraine Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Migraine Drugs by Application
  1. 5.1 Migraine Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Household Use
  5. 5.1.4 Others
  6. 5.2 Global Migraine Drugs Market Size by Application
  7. 5.2.1 Global Migraine Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Migraine Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Migraine Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Migraine Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Migraine Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Migraine Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Migraine Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Migraine Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott
  2. 6.1.1 Abbott Company Information
  3. 6.1.2 Abbott Business Overview
  4. 6.1.3 Abbott Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Migraine Drugs Product Portfolio
  6. 6.1.5 Abbott Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Migraine Drugs Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Migraine Drugs Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly Migraine Drugs Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Migraine Drugs Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Migraine Drugs Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Bayer
  38. 6.7.1 Bayer Company Information
  39. 6.7.2 Bayer Business Overview
  40. 6.7.3 Bayer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bayer Migraine Drugs Product Portfolio
  42. 6.7.5 Bayer Recent Developments
  43. 6.8 Winston Pharmaceuticals
  44. 6.8.1 Winston Pharmaceuticals Company Information
  45. 6.8.2 Winston Pharmaceuticals Business Overview
  46. 6.8.3 Winston Pharmaceuticals Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Winston Pharmaceuticals Migraine Drugs Product Portfolio
  48. 6.8.5 Winston Pharmaceuticals Recent Developments
  49. 6.9 Teva
  50. 6.9.1 Teva Company Information
  51. 6.9.2 Teva Business Overview
  52. 6.9.3 Teva Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Teva Migraine Drugs Product Portfolio
  54. 6.9.5 Teva Recent Developments
  55. 6.10 Kowa Pharmaceuticals America
  56. 6.10.1 Kowa Pharmaceuticals America Company Information
  57. 6.10.2 Kowa Pharmaceuticals America Business Overview
  58. 6.10.3 Kowa Pharmaceuticals America Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Kowa Pharmaceuticals America Migraine Drugs Product Portfolio
  60. 6.10.5 Kowa Pharmaceuticals America Recent Developments
  61. 6.11 Impax
  62. 6.11.1 Impax Company Information
  63. 6.11.2 Impax Business Overview
  64. 6.11.3 Impax Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Impax Migraine Drugs Product Portfolio
  66. 6.11.5 Impax Recent Developments
  67. 6.12 GlaxoSmithKline
  68. 6.12.1 GlaxoSmithKline Company Information
  69. 6.12.2 GlaxoSmithKline Business Overview
  70. 6.12.3 GlaxoSmithKline Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 GlaxoSmithKline Migraine Drugs Product Portfolio
  72. 6.12.5 GlaxoSmithKline Recent Developments
  73. 6.13 Ethypharm
  74. 6.13.1 Ethypharm Company Information
  75. 6.13.2 Ethypharm Business Overview
  76. 6.13.3 Ethypharm Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Ethypharm Migraine Drugs Product Portfolio
  78. 6.13.5 Ethypharm Recent Developments
  79. 6.14 Endo International
  80. 6.14.1 Endo International Company Information
  81. 6.14.2 Endo International Business Overview
  82. 6.14.3 Endo International Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Endo International Migraine Drugs Product Portfolio
  84. 6.14.5 Endo International Recent Developments
  85. 6.15 AstraZeneca
  86. 6.15.1 AstraZeneca Company Information
  87. 6.15.2 AstraZeneca Business Overview
  88. 6.15.3 AstraZeneca Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 AstraZeneca Migraine Drugs Product Portfolio
  90. 6.15.5 AstraZeneca Recent Developments
  91. 6.16 Allergan
  92. 6.16.1 Allergan Company Information
  93. 6.16.2 Allergan Business Overview
  94. 6.16.3 Allergan Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Allergan Migraine Drugs Product Portfolio
  96. 6.16.5 Allergan Recent Developments
7 North America by Country
  1. 7.1 North America Migraine Drugs Sales by Country
  2. 7.1.1 North America Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Migraine Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Migraine Drugs Market Size by Country
  6. 7.2.1 North America Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Migraine Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Migraine Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Migraine Drugs Sales by Country
  2. 8.1.1 Europe Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Migraine Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Migraine Drugs Market Size by Country
  6. 8.2.1 Europe Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Migraine Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Migraine Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Migraine Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Migraine Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Migraine Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Migraine Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Migraine Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Migraine Drugs Sales by Country
  2. 10.1.1 South America Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Migraine Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Migraine Drugs Market Size by Country
  6. 10.2.1 South America Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Migraine Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Migraine Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Migraine Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Migraine Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Migraine Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Migraine Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Migraine Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Migraine Drugs Value Chain Analysis
  2. 12.1.1 Migraine Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Migraine Drugs Production Mode & Process
  7. 12.2 Migraine Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Migraine Drugs Distributors
  10. 12.2.3 Migraine Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst